320 related articles for article (PubMed ID: 33387279)
21. Shortened telomere length in peripheral blood leukocytes is associated with cumulative radioactive iodine doses in patients with differentiated thyroid carcinoma.
Choi H; Cho SW; Kim HH; Yi KH; Park DJ; Park YJ
Cancer; 2024 Jun; 130(12):2215-2223. PubMed ID: 38376914
[TBL] [Abstract][Full Text] [Related]
22. Thyroid Remnant Estimation by Diagnostic Dose (131)I Scintigraphy or (99m)TcO4(-) Scintigraphy after Thyroidectomy: A Comparison with Therapeutic Dose (131)I Imaging.
Liu G; Li N; Li X; Chen S; Du B; Li Y
Biomed Res Int; 2016; 2016():4763824. PubMed ID: 27034938
[TBL] [Abstract][Full Text] [Related]
23. Clinical outcomes of low-dose and high-dose postoperative radioiodine therapy in patients with intermediate-risk differentiated thyroid cancer.
Jeong JH; Kong EJ; Jeong SY; Lee SW; Cho IH; Ah Chun K; Lee J; Ahn BC
Nucl Med Commun; 2017 Mar; 38(3):228-233. PubMed ID: 27984538
[TBL] [Abstract][Full Text] [Related]
24. The prevalence of thyroglossal tract thyroid tissue on SPECT/CT following (131) I ablation therapy after total thyroidectomy for thyroid cancer.
Barber TW; Cherk MH; Topliss DJ; Serpell JW; Yap KS; Bailey M; Kalff V
Clin Endocrinol (Oxf); 2014 Aug; 81(2):266-70. PubMed ID: 24483626
[TBL] [Abstract][Full Text] [Related]
25. Radioactive iodine administered for thyroid remnant ablation following recombinant human thyroid stimulating hormone preparation also has an important adjuvant therapy function.
Tuttle RM; Lopez N; Leboeuf R; Minkowitz SM; Grewal R; Brokhin M; Omry G; Larson S
Thyroid; 2010 Mar; 20(3):257-63. PubMed ID: 20187781
[TBL] [Abstract][Full Text] [Related]
26. Factors influencing radioiodine uptake after thyroid cancer surgery.
Bai JB; Shakerian R; Westcott JD; Lichtenstein M; Miller JA
ANZ J Surg; 2015; 85(7-8):572-7. PubMed ID: 23964714
[TBL] [Abstract][Full Text] [Related]
27. Relapse-free survival after adjuvant radioactive iodine therapy in patients with differentiated thyroid carcinoma with a microscopically positive tumor margin.
Watanabe K; Igarashi T; Uchiyama M; Ojiri H
Ann Nucl Med; 2020 Dec; 34(12):920-925. PubMed ID: 32940889
[TBL] [Abstract][Full Text] [Related]
28. Decreasing the dose of radioiodine for remnant ablation does not increase structural recurrence rates in papillary thyroid carcinoma.
Kruijff S; Aniss AM; Chen P; Sidhu SB; Delbridge LW; Robinson B; Clifton-Bligh RJ; Roach P; Gill AJ; Learoyd D; Sywak MS
Surgery; 2013 Dec; 154(6):1337-44; discussion 1344-5. PubMed ID: 24383104
[TBL] [Abstract][Full Text] [Related]
29. Rebound thymic hyperplasia detected by 18F-FDG PET/CT after radioactive iodine ablation therapy for thyroid cancer.
Jeon TJ; Lee YS; Lee JH; Chang HS; Ryu YH
Thyroid; 2014 Nov; 24(11):1636-41. PubMed ID: 25065897
[TBL] [Abstract][Full Text] [Related]
30. Comparison of Empiric Versus Whole-Body/-Blood Clearance Dosimetry-Based Approach to Radioactive Iodine Treatment in Patients with Metastases from Differentiated Thyroid Cancer.
Deandreis D; Rubino C; Tala H; Leboulleux S; Terroir M; Baudin E; Larson S; Fagin JA; Schlumberger M; Tuttle RM
J Nucl Med; 2017 May; 58(5):717-722. PubMed ID: 27738010
[TBL] [Abstract][Full Text] [Related]
31. Prescribing 131Iodine based on neck uptake produces effective thyroid ablation and reduced hospital stay.
Hodgson DC; Brierley JD; Tsang RW; Panzarella T
Radiother Oncol; 1998 Jun; 47(3):325-30. PubMed ID: 9681898
[TBL] [Abstract][Full Text] [Related]
32. Low-dose radioiodine therapy for patients with intermediate- to high-risk differentiated thyroid cancer.
Abe K; Ishizaki U; Ono T; Horiuchi K; Kanaya K; Sakai S; Okamoto T
Ann Nucl Med; 2020 Feb; 34(2):144-151. PubMed ID: 31834567
[TBL] [Abstract][Full Text] [Related]
33. Differentiated Thyroid Cancer lymph-node relapse. Role of adjuvant radioactive iodine therapy after lymphadenectomy.
Piccardo A; Puntoni M; Bottoni G; Treglia G; Foppiani L; Bertoli M; Catrambone U; Arlandini A; Dib B; Altrinetti V; Massollo M; Bossert I; Cabria M; Bertagna F; Giovanella L
Eur J Nucl Med Mol Imaging; 2017 Jun; 44(6):926-934. PubMed ID: 27966046
[TBL] [Abstract][Full Text] [Related]
34. Impact on testicular function of a single ablative activity of 3.7 GBq radioactive iodine for differentiated thyroid carcinoma.
Bourcigaux N; Rubino C; Berthaud I; Toubert ME; Donadille B; Leenhardt L; Petrot-Keller I; Brailly-Tabard S; Fromigué J; de Vathaire F; Simon T; Siffroi JP; Schlumberger M; Bouchard P; Christin-Maitre S
Hum Reprod; 2018 Aug; 33(8):1408-1416. PubMed ID: 29912343
[TBL] [Abstract][Full Text] [Related]
35. Comparison of Survival Outcomes Following Postsurgical Radioactive Iodine Versus External Beam Radiation in Stage IV Differentiated Thyroid Carcinoma.
Yang Z; Flores J; Katz S; Nathan CA; Mehta V
Thyroid; 2017 Jul; 27(7):944-952. PubMed ID: 28446057
[TBL] [Abstract][Full Text] [Related]
36. The utility of radioiodine scans prior to iodine 131 ablation in patients with well-differentiated thyroid cancer.
Van Nostrand D; Aiken M; Atkins F; Moreau S; Garcia C; Acio E; Burman K; Wartofsky L
Thyroid; 2009 Aug; 19(8):849-55. PubMed ID: 19281428
[TBL] [Abstract][Full Text] [Related]
37. Should patients with remnants from thyroid microcarcinoma really not be treated with iodine-131 ablation?
Gallicchio R; Giacomobono S; Capacchione D; Nardelli A; Barbato F; Nappi A; Pellegrino T; Storto G
Endocrine; 2013 Oct; 44(2):426-33. PubMed ID: 23536285
[TBL] [Abstract][Full Text] [Related]
38. Clinicopathologic risk factors of radioactive iodine therapy based on response assessment in patients with differentiated thyroid cancer: a multicenter retrospective cohort study.
Kwon SY; Lee SW; Kong EJ; Kim K; Kim BI; Kim J; Kim H; Park SH; Park J; Park HL; Oh SW; Won KS; Ryu YH; Yoon JK; Lee SJ; Lee JJ; Chong A; Jeong YJ; Jeong JH; Cho YS; Cho A; Cheon GJ; Choi EK; Hwang JP; Bae SK;
Eur J Nucl Med Mol Imaging; 2020 Mar; 47(3):561-571. PubMed ID: 31820047
[TBL] [Abstract][Full Text] [Related]
39. Impact of 18F-FDG PET/CT on Clinical Management of Suspected Radio-Iodine Refractory Differentiated Thyroid Cancer (RAI-R-DTC).
Lodi Rizzini E; Repaci A; Tabacchi E; Zanoni L; Vicennati V; Cavicchi O; Pagotto U; Morganti AG; Fanti S; Monari F
Diagnostics (Basel); 2021 Aug; 11(8):. PubMed ID: 34441364
[TBL] [Abstract][Full Text] [Related]
40. Incremental diagnostic value of SPECT/CT with 131I scintigraphy after radioiodine therapy in patients with well-differentiated thyroid carcinoma.
Maruoka Y; Abe K; Baba S; Isoda T; Sawamoto H; Tanabe Y; Sasaki M; Honda H
Radiology; 2012 Dec; 265(3):902-9. PubMed ID: 23012466
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
